Drug Topics
OCTOBER 23, 2024
A study found that children aged 6 months or younger who are not eligible for vaccination were at the highest risk for hospitalization due to SARS-CoV-2.
PharmaVoice
OCTOBER 23, 2024
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 23, 2024
New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.
Fierce Pharma
OCTOBER 23, 2024
The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and Wegovy, claiming the drugs are too complex to safely replicate.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
OCTOBER 23, 2024
Abrysvo is the only RSV vaccine approved for use in this age group.
Pharmacy Times
OCTOBER 23, 2024
Pharmacists can educate patients about how to recognize unsafe online sources of medications and ensure patients are properly educate on how to administer their medications.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
OCTOBER 23, 2024
Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.
Drug Topics
OCTOBER 23, 2024
In a comprehensive literature review, researchers addressed the impact cardiac surgery has on gastrointestinal outcomes.
Fierce Pharma
OCTOBER 23, 2024
While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. | Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court. That said, Regeneron is appealing the decision and stressed that it continues to believe Amgen's copycat infringes multiple Eylea patents.
Drug Topics
OCTOBER 23, 2024
Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses what sessions he is looking forward to and key themes he expects to be the topic of conversation at NCPA 2024.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 23, 2024
The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.
STAT
OCTOBER 23, 2024
New research calls into question the high-profile conclusion of the first major study to show that the race of physicians influences health outcomes. In August of 2020, a study published in the Proceedings of the National Academies of Science made headlines with its finding that Black infants were half as likely to survive to their first birthday when they were cared for by white doctors instead of Black ones.
Pharmacy Times
OCTOBER 23, 2024
Benefits include reducing serious health consequences, such as hospitalization and death, as well as the economic burden on health systems due to influenza infection.
STAT
OCTOBER 23, 2024
Science Corporation published preliminary data from a late stage, multi-center clinical trial of a retinal implant that showed promising results Tuesday. Using this prosthetic, scientists partially restored vision to people whose central visual field has holes or blurry spots. Trial participants could read text and recognize playing cards when using the implant, even though they were legally blind.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The Guardian - Pharmaceutical Industry
OCTOBER 23, 2024
‘Surprising’ finding by Australian-led study is first recorded instance of one antibiotic causing resistance to another in a different class Follow our Australia news live blog for latest updates Get our breaking news email , free app or daily news podcast The rise of an almost untreatable superbug has been linked to a common antibiotic, an Australian-led study has found.
STAT
OCTOBER 23, 2024
Most state Medicaid programs don’t cover the new class of weight loss drugs for obesity, but that could soon change. Half of those that don’t are considering adding coverage, per a new KFF report. While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs for obesity.
Pharmacy Times
OCTOBER 23, 2024
Ginger Blackmon, PharmD, will discuss enhancing patient cancer care through implementation of medically integrated oncology team and NCODA’s PQI resources.
STAT
OCTOBER 23, 2024
Linda Barbour thought she was more interested in the Change Healthcare cyberattack than most. Having worked as a medical director for several large health insurance companies and having suffered through the Change fiasco herself as a rehab doctor with a private practice in Kansas City, she figured that if her data had been exposed in that February breach, she would have been notified by now.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
OCTOBER 23, 2024
Anthem Blue Cross Blue Shield of New York’s directory of doctors is thoroughly inaccurate and forces patients to seek costly out-of-network care and delay care, a class-action lawsuit alleges. | Anthem Blue Cross Blue Shield of New York is making it hard for members to receive care from mental health professionals due to poorly run provider directories, or ghost networks, a lawsuit claims.
STAT
OCTOBER 23, 2024
LONDON — For the second time in a matter of months, the U.K.’s cost-effectiveness watchdog has said the limited benefits of a newly approved Alzheimer’s drug do not justify its costs, threatening the possibility of the medicine reaching patients. The National Institute for Health and Care Excellence said in draft guidance released Wednesday that the drug, Eli Lilly’s donanemab, “cannot currently be considered good value for the taxpayer,” given the
Fierce Healthcare
OCTOBER 23, 2024
LAS VEGAS—Atropos Health's large language model for real-world evidence is now ready for prime time after a successful beta program. | Atropos Health's large language model for real-world evidence is now ready for prime time after a successful beta program.
STAT
OCTOBER 23, 2024
The opioid and overdose crisis is a national tragedy, claiming more than 1 million lives since 1999. In the past three years, more than $55 billion has flowed into state, county, and city coffers from opioid manufacturers, distributors, and chain pharmacies as a result of their collective role in instigating and perpetuating this public health crisis.
Fierce Healthcare
OCTOBER 23, 2024
LAS VEGAS — Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend. | LAS VEGAS — Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend.
STAT
OCTOBER 23, 2024
WASHINGTON — When Congress returns on Nov. 12 after the elections, lawmakers will have just over a month to fund the government. That deadline pressure creates an opportunity to potentially enact health care legislation. Regardless of what happens this year, next year will be huge for health care policy, in part because lawmakers need to address major expiring policies.
Fierce Healthcare
OCTOBER 23, 2024
Sanford Health and Marshfield Clinic Health System have signed a merger agreement, the health systems announced on Wednesday, after first revealing their intent to combine in July. | Sanford Health and Marshfield Clinic Health System have signed a merger agreement, the health systems announced on Wednesday, after first revealing their intent to combine in July.
pharmaphorum
OCTOBER 23, 2024
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by these manufacturers.
Fierce Pharma
OCTOBER 23, 2024
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP), pneumococcal conjugate vaccines (PCV) from Pfizer and | The CDC's immunization committee voted to expand the recommendation for pneumococcal conjugate vaccines, including both Pfizer’s Prevnar 20 and Merck’s newer Capvaxive.
pharmaphorum
OCTOBER 23, 2024
US lawmakers fear Pfizer and Lilly's recent forays into direct-to-consumer distribution of medicines via telehealth could violate anti-kickback laws.
Pharmaceutical Technology
OCTOBER 23, 2024
A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.
Pharmacy Times
OCTOBER 23, 2024
Dispensing, communicating, and recording information may look different at each center.
STAT
OCTOBER 23, 2024
Does anyone here listen to Who Weekly? They sort celebrities into “Whos” (the not-as-famous) and “Thems” (the universally-well-known). So, like: RFK is a Them, while Casey and Calley Means are Whos. The study below on sense of smell and breathing made me think: What’s the Who-to-Them ranking of the five senses? First I thought smell was the Whoiest, but my editor wisely suggested touch as the sense people most often forget.
Pharmacy Times
OCTOBER 23, 2024
The agency does not intend to take action against the plaintiffs for the violation of the Federal Food, Drug, and Cosmetic Act, including the compounding of tirzepatide.
STAT
OCTOBER 23, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. It’s been a while since I shared some local news: Chicago has yet again proved itself not only to be the best, but also the rattiest city in the U.S.
Expert insights. Personalized for you.
551 
Let's personalize your content